secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001493152-22-026760
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix completes dosing in Phase 1 trial of inhaled PUR3100 for acute migraine; data expected Q4 2022
--------------------------------------------------------------------------------

- All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.
- Phase 1 safety, tolerability, and PK data expected in Q4 2022.
- PUR3100 uses iSPERSE dry-powder technology for self-administered inhaled delivery of dihydroergotamine.
- Migraine affects 38M in U.S.; 75% do not get relief from current prescription treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/0001493152-22-026760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer